MAbSilico is a French start-up company developing artificial intelligence-based software solutions for therapeutic antibody discovery and development. Our solutions allow biotech and biopharma to accelerate their antibody development pipeline with the objective to tackle down the risk of new drug development failure and drastically minimize development time by 100.